Feb 24 (Reuters) - Regis Healthcare Ltd (REG)
- Anticipates H2 ebitda to be in line with H1 result
- Total capex spend in FY17 is anticipated to be in order of $160 MLN
- FY17 net rad inflows are anticipated to be circa $100 MLN following first half result of $46.6 MLN
- FY17 depreciation expense range is anticipated to be $28 MLN - $31 MLN, following a H1 expense of $14.2MLN
- Interest expense for FY17 is anticipated to be circa $8 MLN for full year
- Debt will remain at approximately 2X ebitda in FY2017
News: REG Regis Healthcare anticipates H2 ebitda to be in line with H1
Add REG (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.70 |
Change
0.260(4.04%) |
Mkt cap ! $1.755B | |||
| Open | High | Low | Value | Volume |
| $6.49 | $6.81 | $6.48 | $4.017M | 598.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 4399 | $6.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.72 | 2498 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| REG (ASX) Chart |
